Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?

Abstract

Get full access to this article

View all access options for this article.

References

De Stefano

Giorgio

Battaglini

et al . Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler 2018; 24: 222–226.

Sastre-Garriga

Tur

Pareto

et al . Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Mult Scler 2015; 21(6): 749–756.

Gold

Radue

E-W

Giovannoni

et al . Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol 2016; 16: 117.

De Stefano

Silva

Barnett

. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs 2017; 31(4): 289–305.